@NP	Ex vivo non-viral vector-mediated neurotrophin-3	1
@NP	Ex vivo	1
@NP	non-viral vector-mediated neurotrophin-3	9
@NP	gene	50
@NP	transfer to olfactory ensheathing glia : effects on axonal regeneration	55
@NP	transfer to olfactory ensheathing glia	55
@NP	transfer	55
@NP	olfactory ensheathing glia	67
@NP	effects on axonal regeneration	95
@NP	effects	95
@NP	axonal regeneration	106
@NP	functional recovery after implantation in rats with spinal cord injury Jun	130
@NP	functional recovery	130
@NP	implantation in rats with spinal cord injury Jun	156
@NP	implantation	156
@NP	rats with spinal cord injury Jun	172
@NP	rats	172
@NP	spinal cord injury Jun	182
@NP	WU , Tian-Sheng SUN , Ji-Xin REN , Xian-Zhang WANG Abstract	206
@NP	WU	206
@NP	Tian-Sheng SUN	210
@NP	Ji-Xin REN	226
@NP	Xian-Zhang WANG Abstract	238
@NP	Objective	265
@NP	olfactory ensheathing glia -LRB- OEG -RRB- implantation	283
@NP	OEG	311
@NP	ex vivo non-viral vector-based neurotrophin - 3 -LRB- NT-3 -RRB- gene therapy	334
@NP	ex vivo non-viral vector-based neurotrophin	334
@NP	ex vivo	334
@NP	non-viral vector-based neurotrophin	342
@NP	3 -LRB- NT-3 -RRB- gene therapy	379
@NP	3 -LRB- NT-3 -RRB-	379
@NP	gene therapy	388
@NP	regeneration	426
@NP	thoracic spinal cord injury -LRB- SCI -RRB-	445
@NP	thoracic spinal cord injury	445
@NP	SCI	474
@NP	Methods Primary OEG	480
@NP	cationic liposome-mediated recombinant plasmid pcDNA3 .1	522
@NP	+	578
@NP	- NT3 and subsequently implanted into adult Wistar rats	580
@NP	NT3	581
@NP	adult Wistar rats	617
@NP	the thoracic spinal cord -LRB- T9 -RRB- contusion	650
@NP	the New York University impactor	693
@NP	The animals in 3 different groups	727
@NP	The animals	727
@NP	3 different groups	742
@NP	4 × 105 OEG transfected with pcDNA3 .1	770
@NP	4 × 105 OEG	770
@NP	4 ×	770
@NP	105 OEG	772
@NP	pcDNA3 .1	797
@NP	+	806
@NP	NT3	809
@NP	pcDNA3 .1	816
@NP	+	825
@NP	plasmids , or the OEGs	828
@NP	plasmids	828
@NP	the OEGs	841
@NP	any plasmid	858
@NP	transfection , respectively ; the fourth group	870
@NP	transfection , respectively	870
@NP	transfection	870
@NP	the fourth group	898
@NP	untreated group , in	919
@NP	untreated group	919
@NP	no OEG	945
@NP	Results NT-3 production was seen	967
@NP	Results	967
@NP	NT-3 production	975
@NP	both ex vivo	1010
@NP	pcDNA3 .1 -LRB- + -RRB-	1038
@NP	pcDNA3 .1	1038
@NP	+	1047
@NP	NT3 transfected OEGs	1050
@NP	NT3	1050
@NP	OEGs	1066
@NP	Three months	1072
@NP	implantation of NT-3-transfected OEGs	1091
@NP	implantation	1091
@NP	NT-3-transfected OEGs	1107
@NP	behavioral analysis	1130
@NP	the hindlimb function of SCI rats	1164
@NP	the hindlimb function	1164
@NP	SCI rats	1189
@NP	All spinal cords	1212
@NP	neurofilament-positive axons	1258
@NP	Retrograde tracing	1288
@NP	Retrograde	1288
@NP	Conclusion Non-viral vector-mediated genetic engineering of OEG	1356
@NP	Conclusion Non-viral vector-mediated genetic engineering	1356
@NP	OEG	1416
@NP	NT - 3	1461
@NP	NT	1461
@NP	3	1465
@NP	axonal outgrowth	1481
@NP	SCI recovery	1520
@NP	rats	1536
@NP	1 Introduction Impairment	1543
@NP	motor and sensory function following spinal cord injury -LRB- SCI -RRB-	1572
@NP	motor and sensory function	1572
@NP	spinal cord injury -LRB- SCI -RRB-	1609
@NP	spinal cord injury	1609
@NP	SCI	1629
@NP	disruption of descending motor pathways and ascending sensory ones	1657
@NP	disruption	1657
@NP	motor pathways	1682
@NP	sensory ones	1711
@NP	SCI	1731
@NP	very little regenerative response	1736
@NP	the adult mammalian central nervous system -LRB- CNS -RRB-	1780
@NP	the adult mammalian central nervous system	1780
@NP	CNS	1824
@NP	permanent loss of function and paralysis	1841
@NP	permanent loss	1841
@NP	function and paralysis	1859
@NP	There	1883
@NP	no available therapy for restoration of function at present	1892
@NP	no available therapy	1892
@NP	restoration of function at present	1917
@NP	restoration	1917
@NP	function at present	1932
@NP	function	1932
@NP	Many investigators	1953
@NP	strategies	1988
@NP	the restoration of function	2003
@NP	the restoration	2003
@NP	function	2022
@NP	SCI	2046
@NP	cellular transplantation	2055
@NP	a promising strategy -LSB- 1-3 -RSB-	2095
@NP	a promising strategy	2095
@NP	1-3 -RSB-	2116
@NP	Both normal and transected olfactory axons	2122
@NP	normal	2127
@NP	transected olfactory axons	2138
@NP	the unusual property	2170
@NP	adult CNS , find their appropriate targets ,	2218
@NP	adult CNS	2218
@NP	their appropriate targets	2234
@NP	synaptic contacts	2270
@NP	them	2293
@NP	4 -RSB-	2298
@NP	A critical element	2302
@NP	the ability of olfactory axons to regenerate and form specific connections	2324
@NP	the ability	2324
@NP	olfactory axons	2339
@NP	specific connections	2378
@NP	the presence	2402
@NP	a unique supporting cell , the olfactory ensheathing glia -LRB- OEG -RRB-	2418
@NP	a unique supporting cell	2418
@NP	the olfactory ensheathing glia -LRB- OEG -RRB-	2444
@NP	the olfactory ensheathing glia	2444
@NP	OEG	2476
@NP	These cells uniquely present	2482
@NP	These cells	2482
@NP	Schwann cell-like and astrocyte-like characteristics	2516
@NP	5 -RSB-	2569
@NP	great potential	2589
@NP	damaged spinal cord -LSB- 2,5-9 -RSB-	2615
@NP	damaged spinal cord	2615
@NP	2,5-9 -RSB-	2635
@NP	not all axonal populations	2652
@NP	OEG implants -LSB- 10 -RSB-	2689
@NP	OEG implants	2689
@NP	10 -RSB-	2702
@NP	Additional vector-mediated neurotrophin	2707
@NP	their regeneration-supporting properties	2771
@NP	endogenous neurotrophic factor expressed by OEG	2821
@NP	endogenous neurotrophic factor	2821
@NP	OEG	2865
@NP	11,12 -RSB-	2876
@NP	Neurotrophins	2884
@NP	their beneficial effects	2917
@NP	neurite outgrowth and neuroprotection	2945
@NP	Neurotrophin-3 -LRB- NT-3 -RRB-	2984
@NP	Neurotrophin-3	2984
@NP	NT-3	3000
@NP	one of important factors in regenerative milieu	3009
@NP	one	3009
@NP	important factors in regenerative milieu	3016
@NP	important factors	3016
@NP	regenerative milieu	3037
@NP	variety of physiological effects	3068
@NP	variety	3068
@NP	physiological effects	3079
@NP	nervous system development -LSB- 13 -RSB-	3104
@NP	nervous system development	3104
@NP	13 -RSB-	3131
@NP	Many studies	3136
@NP	the usage of NT-3 stimulating nerve regeneration	3164
@NP	the usage	3164
@NP	NT-3 stimulating nerve regeneration	3177
@NP	the safe and efficient delivery of NT-3 to the site of injury	3218
@NP	the safe and efficient delivery	3218
@NP	NT-3 to the site of injury	3253
@NP	NT-3	3253
@NP	the site of injury	3261
@NP	the site	3261
@NP	injury	3273
@NP	its short half-life and the barrier between brain and vessel	3312
@NP	its short half-life	3312
@NP	the barrier between brain and vessel	3336
@NP	the barrier	3336
@NP	brain and vessel	3356
@NP	Gene transfer technique	3374
@NP	a new strategy	3407
@NP	application of NT-3	3426
@NP	application	3426
@NP	NT-3	3441
@NP	insertion of NT-3 gene	3457
@NP	insertion	3457
@NP	NT-3 gene	3470
@NP	OEG	3485
@NP	NT-3	3515
@NP	the physiological action	3543
@NP	The present experiment	3569
@NP	SCI	3628
@NP	ex vivo	3644
@NP	plasmid-transfected OEG implants	3652
@NP	more conducive conditions for axonal regeneration	3709
@NP	more conducive conditions	3709
@NP	axonal regeneration	3739
@NP	We	3760
@NP	the effects of plasmid vector-mediated hypersecretion of NT-3	3772
@NP	the effects	3772
@NP	plasmid vector-mediated hypersecretion of NT-3	3787
@NP	plasmid vector-mediated hypersecretion	3787
@NP	NT-3	3829
@NP	functional recovery and axonal regeneration	3837
@NP	functional recovery	3837
@NP	axonal regeneration	3861
@NP	thoracic injury	3887
@NP	Anatomical and functional analyses	3904
@NP	regeneration	3959
@NP	animals over a 12-week observation period	3975
@NP	animals	3975
@NP	a 12-week observation period	3988
@NP	2 Materials and methods 2.1 Recombinant plasmid pcDNA3	4019
@NP	2 Materials	4019
@NP	methods 2.1 Recombinant plasmid pcDNA3	4035
@NP	methods	4035
@NP	2.1 Recombinant plasmid pcDNA3	4043
@NP	+	4076
@NP	NT3 production Coding sequence	4079
@NP	NT-3	4113
@NP	PCR	4135
@NP	gene got from rat liver cells	4144
@NP	gene	4144
@NP	rat liver cells	4158
@NP	pcDNA3 .1 -LRB- + -RRB-	4190
@NP	pcDNA3 .1	4190
@NP	+	4199
@NP	eukaryotic expression vector	4202
@NP	Analysis by restricting enzyme digestion and DNA sequencing	4232
@NP	Analysis	4232
@NP	enzyme digestion and DNA sequencing	4256
@NP	enzyme digestion	4256
@NP	DNA sequencing	4277
@NP	the sequence of plasmid	4324
@NP	the sequence	4324
@NP	plasmid	4340
@NP	14 -RSB-	4372
@NP	2.2 Culturing of OEG The isolation of OEG from the olfactory bulb nerve layer	4377
@NP	2.2 Culturing	4377
@NP	OEG The isolation of OEG from the olfactory bulb nerve layer	4394
@NP	The isolation of OEG from the olfactory bulb nerve layer	4398
@NP	The isolation	4398
@NP	OEG from the olfactory bulb nerve layer	4415
@NP	OEG	4415
@NP	the olfactory bulb nerve layer	4424
@NP	15 -RSB-	4486
@NP	newborn Wistar rats	4500
@NP	intraperitoneal injection of a lethal dose of pentobarbital	4535
@NP	intraperitoneal injection	4535
@NP	a lethal dose of pentobarbital	4564
@NP	a lethal dose	4564
@NP	A craniotomy	4612
@NP	sterile conditions	4653
@NP	the olfactory bulb	4682
@NP	The olfactory bulb	4702
@NP	a Petri dish with ice cold HBSS -LRB- Hanks balanced salt solution -RRB-	4760
@NP	a Petri dish	4760
@NP	ice cold HBSS -LRB- Hanks balanced salt solution -RRB-	4778
@NP	ice cold HBSS	4778
@NP	Hanks balanced salt solution	4793
@NP	Hanks	4793
@NP	balanced salt solution	4799
@NP	The bulbs	4824
@NP	ice cold HBSS	4857
@NP	a sterile scalpel blade	4892
@NP	The minced bulb tissue	4917
@NP	5 mL of HBSS	4962
@NP	5 mL	4962
@NP	HBSS	4970
@NP	1 mg/mL trypsin	4980
@NP	37 °C for 15 min	5013
@NP	37 °C	5013
@NP	15 min	5023
@NP	continual shaking	5035
@NP	DMEM -LRB- Sigma -RRB-	5054
@NP	DMEM	5054
@NP	Sigma	5060
@NP	Ham 's F-12 -LRB- DMEM / F-12 ; 1:1 mixture ; Sigma -RRB-	5071
@NP	Ham 's F-12	5071
@NP	Ham 's	5071
@NP	DMEM	5083
@NP	F-12 ; 1:1 mixture ; Sigma	5089
@NP	F-12	5089
@NP	1:1 mixture ; Sigma	5095
@NP	1:1 mixture	5095
@NP	Sigma	5108
@NP	10 % fetal bovine serum -LRB- DF-10S ; Invitrogen -RRB-	5133
@NP	10 % fetal bovine serum	5133
@NP	DF-10S ; Invitrogen	5157
@NP	DF-10S	5157
@NP	Invitrogen	5165
@NP	the trypsinization	5195
@NP	the specimen	5218
@NP	The supernatant	5256
@NP	the cells	5290
@NP	DF-10S	5326
@NP	DF-10S culture medium	5334
@NP	L-glutamine -LRB- 20 mmol/L -RRB-	5374
@NP	L-glutamine	5374
@NP	20 mmol/L	5387
@NP	penicillin/streptomycin -LRB- 10 000 μg/mL -RRB-	5403
@NP	penicillin/streptomycin	5403
@NP	10 000 μg/mL	5428
@NP	10	5428
@NP	000 μg/mL	5431
@NP	the cells	5456
@NP	a 70-μm mesh filter	5481
@NP	An aliquot of cells	5502
@NP	An aliquot	5502
@NP	cells	5516
@NP	viability	5538
@NP	0.1 % trypan blue	5553
@NP	cells	5575
@NP	a hemocytometer	5599
@NP	The cell suspension	5616
@NP	1 × 106 cells/mL	5651
@NP	1 ×	5651
@NP	106 cells/mL	5653
@NP	25 cm2 flask pretreated with poly-D-lysin -LRB- 0.2 mg/mL -RRB-	5682
@NP	25 cm2 flask	5682
@NP	poly-D-lysin -LRB- 0.2 mg/mL -RRB-	5711
@NP	poly-D-lysin	5711
@NP	0.2 mg/mL	5725
@NP	Cells	5737
@NP	7 d	5762
@NP	37 oC with 5 % CO2	5769
@NP	37 oC	5769
@NP	5 % CO2	5780
@NP	culture medium changed every 2 d.	5793
@NP	culture medium	5793
@NP	every 2 d.	5816
@NP	Six days following the plating , OEGs	5827
@NP	Six days	5827
@NP	the plating , OEGs	5846
@NP	the plating	5846
@NP	OEGs	5859
@NP	contaminated cells	5883
@NP	the serum-free medium -LRB- SFM -RRB- instead of DF-10S	5911
@NP	the serum-free medium -LRB- SFM -RRB-	5911
@NP	the serum-free medium	5911
@NP	SFM	5934
@NP	DF-10S	5950
@NP	The SFM	5958
@NP	DMEM	5979
@NP	biotin -LRB- 10 ng/mL -RRB-	5985
@NP	biotin	5985
@NP	10 ng/mL	5993
@NP	insulin -LRB- 5 g/mL -RRB-	6004
@NP	insulin	6004
@NP	5 g/mL	6013
@NP	transferrin -LRB- 50 g/mL -RRB-	6024
@NP	transferrin	6024
@NP	50 g/mL	6037
@NP	sodium selenate -LRB- 5.2 ng/mL -RRB-	6049
@NP	sodium selenate	6049
@NP	5.2 ng/mL	6066
@NP	hydrocortisone -LRB- 10 ng/mL -RRB-	6078
@NP	hydrocortisone	6078
@NP	10 ng/mL	6094
@NP	glutamine -LRB- 292 mg/L -RRB-	6108
@NP	glutamine	6108
@NP	292 mg/L	6119
@NP	cells	6144
@NP	37 °C with 5 % CO2	6168
@NP	37 °C	6168
@NP	5 % CO2	6179
@NP	culture medium	6191
@NP	every 3 d. 2.3 Transfection	6214
@NP	OEG cultures	6245
@NP	cationic liposome	6263
@NP	We	6281
@NP	Lipofectamine2000 -LRB- Invitrogen -RRB-	6289
@NP	Lipofectamine2000	6289
@NP	Invitrogen	6308
@NP	the media	6323
@NP	the plasmids	6345
@NP	OEG	6363
@NP	Transfection procedure	6368
@NP	the instructions of manufacturer	6418
@NP	the instructions	6418
@NP	manufacturer	6438
@NP	one day	6461
@NP	transfection	6476
@NP	cells	6490
@NP	growth medium -LRB- without antibiotics -RRB- in a 24-well plate	6511
@NP	growth medium -LRB- without antibiotics -RRB-	6511
@NP	growth medium	6511
@NP	antibiotics	6534
@NP	a 24-well plate	6550
@NP	they	6574
@NP	90 % -95 % confluent	6588
@NP	90 %	6588
@NP	-95 %	6591
@NP	the time of transfection	6609
@NP	the time	6609
@NP	transfection	6621
@NP	plasmid	6642
@NP	50 μL of Opti-MEM	6653
@NP	50 μL	6653
@NP	Opti-MEM	6662
@NP	I	6671
@NP	Serum Medium	6681
@NP	serum and mix	6702
@NP	Mix Lipofectamine2000	6724
@NP	use , then	6760
@NP	use	6760
@NP	the appropriate amount	6777
@NP	50 μL of Opti-MEM I Medium	6803
@NP	50 μL	6803
@NP	Opti-MEM I Medium	6812
@NP	Opti-MEM	6812
@NP	I Medium	6821
@NP	Mix	6831
@NP	5 min at room temperature	6859
@NP	5 min	6859
@NP	room temperature	6868
@NP	the 5-min incubation	6892
@NP	the diluted DNA with the diluted Lipofectamine2000	6922
@NP	the diluted DNA	6922
@NP	the diluted Lipofectamine2000	6943
@NP	Mix	6974
@NP	20 min at room temperature	7002
@NP	20 min	7002
@NP	room temperature	7012
@NP	the formation of plasmid	7038
@NP	the formation	7038
@NP	plasmid	7055
@NP	Lipofectamine2000 complexes	7064
@NP	the complexes	7097
@NP	each well	7114
@NP	each	7114
@NP	Mix gently by rocking the plate back and forth .	7125
@NP	Mix	7125
@NP	the plate	7147
@NP	the cells	7182
@NP	37 °C in a CO2 incubator for 24-48 h	7195
@NP	37 °C	7195
@NP	a CO2 incubator for 24-48 h	7204
@NP	a CO2 incubator	7204
@NP	24-48 h	7224
@NP	they	7238
@NP	assay for transgene expression	7257
@NP	assay	7257
@NP	transgene expression	7267
@NP	2.4 NT-3 production	7289
@NP	OEG	7326
@NP	The NT-3 levels	7330
@NP	secreted plasmid in conditioned medium from transfected OEG cultures	7349
@NP	secreted plasmid	7349
@NP	conditioned medium from transfected OEG cultures	7369
@NP	conditioned medium	7369
@NP	transfected OEG cultures	7393
@NP	ELISA	7437
@NP	Woodhall et al. -LSB- 12 -RSB-	7460
@NP	Woodhall et al. -LSB-	7460
@NP	The medium	7481
@NP	3 d	7506
@NP	the cultures	7532
@NP	24 h for determination of the production per day	7559
@NP	24 h	7559
@NP	determination of the production per day	7568
@NP	determination	7568
@NP	the production per day	7585
@NP	the production	7585
@NP	day	7604
@NP	The Emax immunoassay system -LRB- Promega -RRB-	7609
@NP	The Emax immunoassay system	7609
@NP	Promega	7638
@NP	the NT-3 levels	7666
@NP	OEG conditioned medium	7685
@NP	The amount of NT-3 secreted from 1 × 105 transfected cells per day	7709
@NP	The amount	7709
@NP	NT-3 secreted from 1 × 105 transfected cells per day	7723
@NP	NT-3	7723
@NP	1 × 105 transfected cells per day	7742
@NP	1 × 105	7742
@NP	cells per day	7760
@NP	cells	7760
@NP	day	7770
@NP	2.5 Biological activity of plasmid vector-derived NT-3	7788
@NP	2.5 Biological activity	7788
@NP	plasmid vector-derived NT-3	7815
@NP	recombinant NT-3 protein	7864
@NP	we	7914
@NP	their effects	7925
@NP	the neurite outgrowth	7942
@NP	human neuroblastoma cells	7967
@NP	Primary human neuroblastoma cells	7994
@NP	The attached cells	8067
@NP	0.05 % trypsin -LRB- Invitrogen -RRB- for 10 min	8106
@NP	0.05 % trypsin -LRB- Invitrogen -RRB-	8106
@NP	0.05 % trypsin	8106
@NP	Invitrogen	8121
@NP	10 min	8137
@NP	the reaction	8154
@NP	DMEM -LRB- Sigma -RRB-	8189
@NP	DMEM	8189
@NP	Sigma	8195
@NP	Ham 's F-12 -LRB- 1:1 ; Sigma -RRB-	8206
@NP	Ham 's F-12	8206
@NP	Ham 's	8206
@NP	1:1 ; Sigma	8218
@NP	1:1	8218
@NP	Sigma	8223
@NP	10 % fetal bovine serum -LRB- DF-10S ; Invitrogen -RRB-	8248
@NP	10 % fetal bovine serum	8248
@NP	DF-10S ; Invitrogen	8272
@NP	DF-10S	8272
@NP	Invitrogen	8280
@NP	The suspension	8293
@NP	serum-free medium	8328
@NP	4 plates	8362
@NP	a density of 1 ×	8374
@NP	a density	8374
@NP	1 ×	8387
@NP	104	8389
@NP	500 μL medium from the cultures of OEGs	8399
@NP	500 μL medium	8399
@NP	the cultures of OEGs	8418
@NP	the cultures	8418
@NP	OEGs	8434
@NP	pcDNA3	8456
@NP	+	8465
@NP	NT3	8468
@NP	pcDNA3 .1	8475
@NP	+	8484
@NP	OEGs without plasmid transfection	8491
@NP	OEGs	8491
@NP	plasmid transfection	8504
@NP	added to	8530
@NP	added	8530
@NP	3 different	8539
@NP	3	8539
@NP	plates	8551
@NP	The rest plate	8559
@NP	serum-free medium	8589
@NP	Three days later	8608
@NP	neurite outgrowth	8626
@NP	2.6 Preparation of OEG for spinal implantation OEG suspensions	8662
@NP	2.6 Preparation	8662
@NP	OEG for spinal implantation OEG suspensions	8681
@NP	OEG	8681
@NP	spinal implantation OEG suspensions	8689
@NP	Ruitenberg	8742
@NP	et al. described -LSB- 16 -RSB-	8753
@NP	et al.	8753
@NP	16 -RSB-	8770
@NP	OEGs	8784
@NP	poly-L-lysine-coated dishes	8806
@NP	a density of 1 ×	8837
@NP	a density	8837
@NP	1 ×	8850
@NP	106 cells in DF-10S	8852
@NP	106 cells	8852
@NP	DF-10S	8865
@NP	The next day	8873
@NP	the medium	8887
@NP	fresh medium	8916
@NP	pcDNA3	8940
@NP	+	8949
@NP	- NT3 or pcDNA3 .1 -LRB- + -RRB- , and cells	8951
@NP	- NT3 or pcDNA3 .1 -LRB- + -RRB-	8951
@NP	NT3	8952
@NP	pcDNA3 .1 -LRB- + -RRB-	8959
@NP	pcDNA3 .1	8959
@NP	cells	8976
@NP	72 h.	8996
@NP	that	9008
@NP	the OEG cultures	9014
@NP	L-15 medium	9048
@NP	trypsinization	9073
@NP	serum-free DMEM/F -12 medium	9108
@NP	cells	9143
@NP	low-speed centrifugation	9166
@NP	appropriate volume of DMEM/F -12	9230
@NP	appropriate volume	9230
@NP	DMEM/F -12	9252
@NP	the OEG suspension	9272
@NP	50 000 / μL	9294
@NP	50 000	9294
@NP	μL	9302
@NP	The viability	9306
@NP	OEG suspensions	9323
@NP	the percentage of dead cells using Trypan blue staining	9371
@NP	the percentage	9371
@NP	dead cells using Trypan blue staining	9389
@NP	dead cells	9389
@NP	Trypan blue staining	9406
@NP	> 95 %	9432
@NP	>	9432
@NP	2.7 Experimental design Wistar rats -LRB- 200-240 g -RRB-	9438
@NP	2.7 Experimental design Wistar rats	9438
@NP	200-240 g	9475
@NP	standard conditions	9504
@NP	a 12/12 h light/dark cycle	9529
@NP	water and food ad libitum	9573
@NP	All experimental procedures	9600
@NP	accordance	9646
@NP	the guidelines of the local Animal Welfare Committee	9662
@NP	the guidelines	9662
@NP	the local Animal Welfare Committee	9680
@NP	use and care of laboratory animals	9719
@NP	use and care	9719
@NP	laboratory animals	9735
@NP	Forty four adult female rats	9755
@NP	the thoracic spinal cord contusion	9802
@NP	four groups	9859
@NP	group 1 -LRB- n = 10 -RRB-	9872
@NP	group 1	9872
@NP	n	9881
@NP	10	9884
@NP	implantation	9922
@NP	groups 2 and 3	9936
@NP	implantation of untransfected OEG -LRB- n = 10 -RRB-	9960
@NP	implantation	9960
@NP	untransfected OEG -LRB- n = 10 -RRB-	9976
@NP	untransfected OEG	9976
@NP	n	9995
@NP	10	9999
@NP	pcDNA3 .1	10006
@NP	+	10015
@NP	OEG -LRB- n = 12 -RRB- , respectively ; and group 4 -LRB- n = 12 -RRB-	10030
@NP	OEG -LRB- n = 12 -RRB- , respectively	10030
@NP	OEG -LRB- n = 12 -RRB-	10030
@NP	OEG	10030
@NP	n	10035
@NP	12	10039
@NP	group 4 -LRB- n = 12 -RRB-	10062
@NP	group 4	10062
@NP	n	10071
@NP	12	10075
@NP	implantation of pcDNA3 .1	10088
@NP	implantation	10088
@NP	pcDNA3 .1	10104
@NP	NT3-transfected OEG	10116
@NP	The recovery of rats ' hindlimb performance	10137
@NP	The recovery	10137
@NP	rats ' hindlimb performance	10153
@NP	rats '	10153
@NP	12 weeks	10205
@NP	Seven days	10215
@NP	implantation , two animals	10232
@NP	implantation	10232
@NP	two animals	10246
@NP	each group	10258
@NP	evaluation of transgene expression	10284
@NP	evaluation	10284
@NP	transgene expression	10298
@NP	Fourteen days	10320
@NP	another two rats from each group	10355
@NP	another two rats	10355
@NP	each group	10377
@NP	fluorochrome -LRB- FG ; Vector Laboratories -RRB-	10419
@NP	fluorochrome	10419
@NP	FG ; Vector Laboratories	10433
@NP	FG	10433
@NP	Vector Laboratories	10437
@NP	2.8 Surgical procedures	10459
@NP	OEG into complete thoracic transection injury model	10499
@NP	OEG	10499
@NP	complete thoracic transection injury model	10508
@NP	detail -LSB- 16 -RSB-	10579
@NP	detail	10579
@NP	16 -RSB-	10586
@NP	brief	10594
@NP	animals	10601
@NP	laminectomy	10641
@NP	T9-T10	10656
@NP	they	10673
@NP	a 25 g/cm	10694
@NP	spinal cord contusion using the New York University impactor -LSB- 17 -RSB-	10704
@NP	spinal cord contusion	10704
@NP	the New York University impactor -LSB- 17 -RSB-	10732
@NP	the New York University impactor	10732
@NP	17 -RSB-	10765
@NP	a technically complete injury	10775
@NP	the OEG	10820
@NP	the middle of spinal cord	10857
@NP	the middle	10857
@NP	spinal cord	10871
@NP	1 mm distance , both proximal and distal ,	10886
@NP	1 mm distance	10886
@NP	the edges of the lesion area	10932
@NP	the edges	10932
@NP	the lesion area	10945
@NP	dorsal	10978
@NP	cells	10986
@NP	the following four sites of each cord stump	11011
@NP	the following four sites	11011
@NP	each cord stump	11039
@NP	ventral	11060
@NP	funiculus ,	11068
@NP	funiculus	11068
@NP	gray	11083
@NP	commissure ,	11088
@NP	commissure	11088
@NP	-LRB- 3 -RRB- dorsal corticospinal tract , and -LRB- 4 -RRB-	11100
@NP	-LRB- 3 -RRB- dorsal corticospinal tract	11100
@NP	dorsal	11104
@NP	tract	11125
@NP	-LRB- 4 -RRB-	11136
@NP	fasciculus	11148
@NP	Coordinates of the four injection sites	11160
@NP	Coordinates	11160
@NP	the four injection sites	11175
@NP	1.75 mm , 1.25 mm , 1 mm , and 0.5 mm	11205
@NP	1.75 mm	11205
@NP	1.25 mm	11214
@NP	1 mm	11223
@NP	0.5 mm	11233
@NP	Each site	11255
@NP	1 L of a suspension containing 5 × 104 cells	11274
@NP	1 L	11274
@NP	a suspension containing 5 × 104 cells	11283
@NP	a suspension	11283
@NP	5 × 104 cells	11307
@NP	5 ×	11307
@NP	104 cells	11309
@NP	we	11329
@NP	total 2 × 105 cells	11341
@NP	each cord stump	11364
@NP	Injections	11381
@NP	a sterile glass micropipette , Hamilton syringe , and a micromanipulator	11413
@NP	a sterile glass micropipette	11413
@NP	Hamilton syringe	11443
@NP	a micromanipulator	11465
@NP	All animals	11485
@NP	a postoperative subcutaneous injection of 2 mL physiological salt solution	11506
@NP	a postoperative subcutaneous injection	11506
@NP	2 mL physiological salt solution	11548
@NP	2 mL	11548
@NP	blood loss	11599
@NP	their bladders	11615
@NP	reflexes	11663
@NP	The rats	11682
@NP	pairs in separate cages	11710
@NP	pairs	11710
@NP	separate cages	11719
@NP	the end of surgical procedures	11738
@NP	the end	11738
@NP	surgical procedures	11749
@NP	the viability of OEG suspensions used for implantation	11770
@NP	the viability	11770
@NP	OEG suspensions used for implantation	11787
@NP	OEG suspensions	11787
@NP	implantation	11812
@NP	between 90 % and 95 %	11838
@NP	determined by Trypan blue staining	11861
@NP	Trypan	11875
@NP	2.9 In vivo transgene expression RT-PCR	11897
@NP	2.9 In vivo transgene expression	11897
@NP	2.9	11897
@NP	In vivo transgene expression	11901
@NP	RT-PCR	11930
@NP	7 d	11951
@NP	implantation	11961
@NP	transgene expression	11986
@NP	total cellular mRNA	12017
@NP	the injury area	12055
@NP	Test Kit following the manufacturer 's instructions	12080
@NP	Test Kit	12080
@NP	the manufacturer 's instructions	12099
@NP	the manufacturer 's	12099
@NP	The resulting cDNA	12132
@NP	PCR	12168
@NP	PCR reaction	12173
@NP	25 μL volume containing	12203
@NP	25 μL volume	12203
@NP	2 μL	12228
@NP	cDNA , 2 U of Taq polymerase , 2 μL primers -LRB- forward and reverse -RRB-	12236
@NP	cDNA	12236
@NP	2 U of Taq polymerase , 2 μL primers -LRB- forward and reverse -RRB-	12242
@NP	2 U of Taq polymerase	12242
@NP	2 U	12242
@NP	Taq polymerase	12249
@NP	2 μL primers -LRB- forward and reverse -RRB-	12265
@NP	2 μL primers	12265
@NP	3 μL beta-actin -LRB- inner reference -RRB-	12305
@NP	3 μL beta-actin	12305
@NP	inner reference	12322
@NP	Reaction conditions	12340
@NP	94 °C for 10 min	12368
@NP	94 °C	12368
@NP	10 min	12378
@NP	94 °C for 1 min	12394
@NP	94 °C	12394
@NP	1 min	12404
@NP	55 °C	12414
@NP	1 min	12424
@NP	72 °C for 1 min	12438
@NP	72 °C	12438
@NP	1 min	12448
@NP	35 cycles ; followed by a final extension at 72 °C for 10 min	12459
@NP	35 cycles	12459
@NP	a final extension	12482
@NP	72 °C for 10 min	12503
@NP	72 °C	12503
@NP	10 min	12513
@NP	2.10 Locomotor analysis	12521
@NP	surgery	12551
@NP	animals	12560
@NP	an open field environment on 1 , 14 , 28 , 42 , 56 , and 84 d post-operation	12587
@NP	an open field environment	12587
@NP	1 , 14 , 28 , 42 , 56 , and 84 d post-operation	12616
@NP	1	12616
@NP	14	12619
@NP	28	12623
@NP	42	12627
@NP	56	12631
@NP	84 d post-operation	12639
@NP	Videotapes	12660
@NP	a blinded scorer	12688
@NP	the Basso Beattie Bresnahan -LRB- BBB -RRB- scores -LSB- 18 -RSB-	12710
@NP	Basso Beattie Bresnahan -LRB- BBB -RRB- scores	12714
@NP	BBB	12739
@NP	each animal at each testing session	12773
@NP	each animal	12773
@NP	each testing session	12788
@NP	Scores from the left and right side	12810
@NP	Scores	12810
@NP	the left and right side	12822
@NP	a single score	12864
@NP	each animal at each testing session	12897
@NP	each animal	12897
@NP	each testing session	12912
@NP	2.11 Retrograde axon tracing The regenerated axons	12934
@NP	2.11 Retrograde axon	12934
@NP	The regenerated axons	12963
@NP	FG	13014
@NP	a neuronal label , 14 d before perfusion	13021
@NP	a neuronal label	13021
@NP	14 d before perfusion	13039
@NP	14 d	13039
@NP	perfusion	13051
@NP	brief	13065
@NP	the animals	13072
@NP	a stereotaxic frame for laminectomy	13097
@NP	a stereotaxic frame	13097
@NP	laminectomy	13121
@NP	deep ketamine -- xylazine anesthesia	13139
@NP	deep ketamine	13139
@NP	xylazine anesthesia	13153
@NP	FG tracer in glass pipettes	13174
@NP	FG tracer	13174
@NP	glass pipettes	13187
@NP	the spinal cord caudad	13232
@NP	the lesion region	13258
@NP	The injector	13277
@NP	place	13302
@NP	5 min	13312
@NP	careful withdrawal of the glass capillary and suturing of the skin	13331
@NP	careful withdrawal of the glass capillary	13331
@NP	careful withdrawal	13331
@NP	the glass capillary	13353
@NP	suturing of the skin	13377
@NP	suturing	13377
@NP	the skin	13389
@NP	2.12 Histological analysis Rats	13399
@NP	12 weeks	13447
@NP	the spinal cords	13476
@NP	immunohistochemical staining of neurofilament -LRB- NF -RRB-	13512
@NP	immunohistochemical staining	13512
@NP	neurofilament -LRB- NF -RRB-	13544
@NP	neurofilament	13544
@NP	NF	13559
@NP	brief	13567
@NP	the anesthetized rats	13574
@NP	cold PBS -LRB- 0.1 mol/L , pH 7.2 -RRB-	13615
@NP	cold PBS	13615
@NP	0.1 mol/L	13625
@NP	pH 7.2	13636
@NP	heparin	13655
@NP	4 % buffered paraformaldehyde	13676
@NP	4 %	13676
@NP	paraformaldehyde	13688
@NP	Spinal cord from the contused site	13706
@NP	Spinal cord	13706
@NP	the contused site	13723
@NP	a 10 % formalin solution for 2 h	13762
@NP	a 10 % formalin solution	13762
@NP	2 h	13790
@NP	paraffin	13807
@NP	4 μm sections	13829
@NP	The sections	13844
@NP	0.3 % H2O2 in methanol	13875
@NP	0.3 % H2O2	13875
@NP	methanol	13888
@NP	the endogenous peroxidase	13911
@NP	nonspecific staining	13942
@NP	3 % normal serum	13980
@NP	Primary antibodies	13997
@NP	NF	14031
@NP	mouse anti-Neurofilament SMI31	14035
@NP	1:1 000 ; Sternberger Monoclonals Inc. , Baltimore	14067
@NP	1:1 000	14067
@NP	Sternberger Monoclonals Inc. , Baltimore	14076
@NP	Sternberger Monoclonals Inc.	14076
@NP	Baltimore	14106
@NP	MD , USA	14117
@NP	1 % normal serum	14141
@NP	the tissue	14169
@NP	sections at 37 °C for 1 h and then at 4 °C overnight	14180
@NP	sections	14180
@NP	37 °C for 1 h	14192
@NP	37 °C	14192
@NP	1 h	14202
@NP	4 °C	14218
@NP	overnight	14223
@NP	Sections	14234
@NP	an appropriate	14263
@NP	secondary antibody	14291
@NP	1:200	14311
@NP	Vector Laboratories , Burlingame , CA , USA	14318
@NP	Vector Laboratories	14318
@NP	Burlingame	14339
@NP	CA	14351
@NP	USA	14355
@NP	ABC complex	14372
@NP	45 min at room temperature	14388
@NP	45 min	14388
@NP	room temperature	14398
@NP	Diaminobenzidine -LRB- DAB-brown color ; Sigma Chemical Co. , St.	14416
@NP	Diaminobenzidine -LRB- DAB-brown color ; Sigma Chemical	14416
@NP	Diaminobenzidine	14416
@NP	DAB-brown color ; Sigma Chemical	14434
@NP	DAB-brown color	14434
@NP	Sigma Chemical	14451
@NP	Co. , St.	14466
@NP	Louis , MO , USA -RRB-	14475
@NP	Louis	14475
@NP	MO	14482
@NP	USA	14486
@NP	the chromatogen	14503
@NP	The sections	14520
@NP	hematoxylin	14558
@NP	alcohols	14592
@NP	The sections stained with normal serum	14615
@NP	The sections	14615
@NP	normal serum	14641
@NP	control	14668
@NP	Omission of primary antibodies	14677
@NP	Omission	14677
@NP	primary antibodies	14689
@NP	only weak , nonspecific labeling of the blood vessels	14720
@NP	only weak	14720
@NP	nonspecific labeling of the blood vessels	14731
@NP	nonspecific labeling	14731
@NP	the blood vessels	14755
@NP	Quantification of the proportional area at the center of the lesion at 40 ×	14774
@NP	Quantification	14774
@NP	the proportional area at the center of the lesion at 40 ×	14792
@NP	the proportional area	14792
@NP	the center of the lesion at 40 ×	14817
@NP	the center	14817
@NP	the lesion at 40 ×	14831
@NP	the lesion	14831
@NP	40 ×	14845
@NP	a computer-assisted digital image analysis system -LRB- MPIAS-500 -RRB-	14872
@NP	a computer-assisted digital image analysis system	14872
@NP	MPIAS-500	14923
@NP	the relative optical density threshold	14959
@NP	positive stained properties within a defined target area	15010
@NP	positive	15010
@NP	properties	15027
@NP	a defined target area	15045
@NP	FG-labeled neurons	15068
@NP	fluorescent microscope	15146
@NP	2.13 Statistical analysis Data	15170
@NP	histological analysis and the BBB scores	15215
@NP	histological analysis	15215
@NP	the BBB scores	15241
@NP	statistical differences	15274
@NP	animal groups using one-way ANOVA and Student-Newman-Keuls tests	15306
@NP	animal groups	15306
@NP	one-way ANOVA and Student-Newman-Keuls tests	15326
@NP	P	15372
@NP	0.05	15376
@NP	All data incorporated in the analysis	15423
@NP	All data	15423
@NP	the analysis	15448
@NP	the animals survived the entire study	15480
@NP	the animals	15480
@NP	the entire study	15501
@NP	3 Results Fig. 1 Human neuroblastoma cells	15520
@NP	3 Results	15520
@NP	1 Human neuroblastoma cells	15535
@NP	medium from olfactory ensheathing glia -LRB- OEG -RRB- cultures	15577
@NP	olfactory ensheathing glia	15589
@NP	OEG	15617
@NP	Moderate extensions of neurites	15632
@NP	Moderate extensions	15632
@NP	neurites	15655
@NP	human neuroblastoma cells	15683
@NP	medium from untransfected or pcDNA3 .1 -LRB- + -RRB-	15730
@NP	medium	15730
@NP	untransfected or pcDNA3 .1 -LRB- + -RRB-	15742
@NP	untransfected or pcDNA3 .1	15742
@NP	+	15768
@NP	transfected OEG -LRB- A , B -RRB-	15771
@NP	transfected OEG	15771
@NP	A , B	15788
@NP	A	15788
@NP	B	15791
@NP	Robust outgrowth of neurites from neuroblastoma cells -LRB- C -RRB-	15795
@NP	Robust outgrowth	15795
@NP	neurites from neuroblastoma cells -LRB- C -RRB-	15815
@NP	neurites	15815
@NP	neuroblastoma cells -LRB- C -RRB-	15829
@NP	neuroblastoma cells	15829
@NP	C	15850
@NP	suspected synapse connection -LRB- D -RRB-	15857
@NP	suspected synapse connection	15857
@NP	D	15887
@NP	medium from the OEG	15906
@NP	medium	15906
@NP	the OEG	15918
@NP	NT-3	15943
@NP	plasmid vector	15958
@NP	Scale bar , 8 μm .	15984
@NP	Scale bar	15984
@NP	8 μm	15995
@NP	Fig. 2 In vivo transgene expression .	16002
@NP	Fig. 2	16002
@NP	In vivo transgene expression	16009
@NP	Lane A	16039
@NP	Lane	16039
@NP	A	16044
@NP	untreated group ; Lane B : OEG group ; Lane C	16047
@NP	untreated group	16047
@NP	Lane B : OEG group	16064
@NP	Lane B	16064
@NP	OEG group	16072
@NP	Lane C	16083
@NP	pcDNA3	16091
@NP	+	16100
@NP	+ OEG group ; Lane D : pcDNA3	16102
@NP	+ OEG	16102
@NP	group ;	16107
@NP	group	16107
@NP	Lane D : pcDNA3	16114
@NP	Lane	16114
@NP	D	16119
@NP	pcDNA3	16122
@NP	1 -LRB- + -RRB- - NT3 + OEG group .	16130
@NP	1	16130
@NP	+	16132
@NP	NT3 + OEG group	16135
@NP	NT3	16135
@NP	OEG group	16139
@NP	The pcDNA3	16150
@NP	+	16163
@NP	- NT3-tansfected OEG group expressed high level of NT-3 mRNA	16165
@NP	- NT3-tansfected OEG group expressed high level of NT-3	16165
@NP	NT3-tansfected	16166
@NP	OEG group	16181
@NP	OEG	16181
@NP	expressed high level of NT-3	16191
@NP	expressed high level	16191
@NP	NT-3	16215
@NP	mRNA	16220
@NP	Fig. 3 -LRB- - -RRB- Fig. 4	16227
@NP	Fig. 3 -LRB- - -RRB-	16227
@NP	Fig. 3	16227
@NP	-	16235
@NP	Fig. 5 Basso Beattie Bresnahan	16251
@NP	-LRB- BBB -RRB- locomotor score -LRB- mean ± SD -RRB-	16282
@NP	-LRB- BBB -RRB- locomotor score	16282
@NP	BBB	16283
@NP	mean ± SD	16305
@NP	mean	16305
@NP	± SD	16309
@NP	rats in different groups	16317
@NP	rats	16317
@NP	different groups	16325
@NP	Rats that received pcDNA3 .1 -LRB- + -RRB- - NT3 transfected OEG revealed active	16343
@NP	Rats	16343
@NP	pcDNA3 .1	16362
@NP	+	16371
@NP	- NT3 transfected OEG revealed active	16373
@NP	- NT3 transfected OEG revealed	16373
@NP	NT3	16374
@NP	OEG revealed	16390
@NP	OEG	16390
@NP	active	16403
@NP	hindlimb movement	16422
@NP	six weeks	16440
@NP	injury	16462
@NP	The only OEG implantation and untreated rats	16470
@NP	The only OEG implantation	16470
@NP	untreated rats	16500
@NP	either paralysis or occasional uncoordinated hindlimb spasms	16525
@NP	paralysis	16532
@NP	occasional uncoordinated hindlimb spasms	16545
@NP	injury	16592
@NP	Differences between every two weeks	16600
@NP	Differences	16600
@NP	every two weeks	16620
@NP	post hoc means-corrected t-test -LRB- P < 0.05 -RRB-	16655
@NP	post hoc means-corrected t-test	16655
@NP	P < 0.05	16688
@NP	P	16688
@NP	< 0.05	16690
@NP	<	16690
@NP	0.05	16692
@NP	3.1 In vitro analysis	16700
@NP	transgenic neurotrophin expression Transfection	16725
@NP	purified OEG cultures with plasmid-liposome complex	16776
@NP	purified OEG cultures	16776
@NP	plasmid-liposome complex	16803
@NP	comparatively high levels of transgene expression	16840
@NP	comparatively high levels	16840
@NP	transgene expression	16869
@NP	many cells	16893
@NP	determined by in situ hybridization	16907
@NP	3 d after infection -LRB- data not shown -RRB-	16946
@NP	3 d	16946
@NP	infection	16956
@NP	data not shown	16967
@NP	data	16967
@NP	Transfection efficiency	16984
@NP	30 %	17019
@NP	fluorescence assay	17040
@NP	Numerous cells	17060
@NP	high levels of NT-3 mRNA	17085
@NP	high levels	17085
@NP	NT-3 mRNA	17100
@NP	signs of toxicity or cytopathological effects	17118
@NP	signs	17118
@NP	toxicity or cytopathological effects	17127
@NP	No staining for any of the transgenes	17165
@NP	No staining	17165
@NP	any of the transgenes	17181
@NP	any	17181
@NP	the transgenes	17188
@NP	untransfected OEGs	17219
@NP	control cultures	17253
@NP	hybridization	17279
@NP	sense probe	17298
@NP	Conditioned medium from transfeced OEG cultures	17311
@NP	Conditioned medium	17311
@NP	transfeced OEG cultures	17335
@NP	the presence of NT-3	17376
@NP	the presence	17376
@NP	NT-3	17392
@NP	an ELISA assay	17403
@NP	4 d	17418
@NP	transfection	17434
@NP	NT-3	17448
@NP	the medium samples	17475
@NP	n	17495
@NP	4	17499
@NP	control or pcDNA3 .1 -LRB- + -RRB-	17513
@NP	control or pcDNA3 .1	17513
@NP	+	17533
@NP	OEG cultures	17548
@NP	transfection	17568
@NP	pcDNA3 .1	17586
@NP	+	17595
@NP	- NT3 , ELISA analysis	17597
@NP	NT3 , ELISA	17598
@NP	NT3	17598
@NP	ELISA	17603
@NP	medium samples	17621
@NP	least -LRB- 21.7 ± 4.8 -RRB- ng of recombinant NT-3 was secreted from 1	17653
@NP	least -LRB- 21.7 ± 4.8 -RRB-	17653
@NP	least	17653
@NP	21.7 ± 4.8	17660
@NP	21.7 ±	17660
@NP	4.8	17665
@NP	ng of recombinant NT-3	17670
@NP	ng	17670
@NP	recombinant NT-3	17676
@NP	1	17711
@NP	× 105 cells	17712
@NP	day	17727
@NP	These results	17732
@NP	the time-point of implantation	17764
@NP	the time-point	17764
@NP	implantation	17782
@NP	high amounts of recombinant neurotrophin	17796
@NP	high amounts	17796
@NP	recombinant neurotrophin	17812
@NP	NT-3-transfected OEG as compared with controls	17856
@NP	NT-3-transfected OEG as	17856
@NP	controls	17894
@NP	Biological activity of plasmid-derived NT-3	17904
@NP	Biological activity	17904
@NP	plasmid-derived NT-3	17927
@NP	a coculture experiment	17968
@NP	this	17996
@NP	human neuroblastoma cells -LRB- n = 12 -RRB-	18002
@NP	human neuroblastoma cells	18002
@NP	n	18029
@NP	12	18033
@NP	medium	18056
@NP	OEG cultures	18068
@NP	the effect of transgenic neurotrophic factor production	18094
@NP	the effect	18094
@NP	transgenic neurotrophic factor production	18108
@NP	neurite outgrowth	18185
@NP	3 d	18206
@NP	the initial plating	18216
@NP	Moderate extensions of neurites	18237
@NP	Moderate extensions	18237
@NP	neurites	18260
@NP	human neuroblastoma cells	18288
@NP	medium from untransfected or pcDNA3 .1 -LRB- + -RRB-	18335
@NP	medium	18335
@NP	untransfected or pcDNA3 .1 -LRB- + -RRB-	18347
@NP	untransfected or pcDNA3 .1	18347
@NP	+	18373
@NP	transfected OEG -LRB- Fig. 1A , B -RRB-	18376
@NP	transfected OEG	18376
@NP	Fig. 1A , B	18393
@NP	Fig. 1A	18393
@NP	B	18402
@NP	No visible differences in radial neurite outgrowth	18406
@NP	No visible differences	18406
@NP	radial neurite outgrowth	18432
@NP	these groups	18479
@NP	plasmid vector transfection	18509
@NP	the growth supporting properties of OEG	18560
@NP	the growth	18560
@NP	properties of OEG	18582
@NP	properties	18582
@NP	OEG	18596
@NP	A robust outgrowth of neurites from neuroblastoma cells	18601
@NP	A robust outgrowth	18601
@NP	neurites from neuroblastoma cells	18623
@NP	neurites	18623
@NP	neuroblastoma cells	18637
@NP	medium from OEG transfected with a plasmid vector-encoding NT-3	18672
@NP	medium	18672
@NP	OEG transfected with a plasmid vector-encoding NT-3	18684
@NP	OEG	18684
@NP	a plasmid vector-encoding NT-3	18705
@NP	Fig. 1C	18747
@NP	These results	18757
@NP	plasmid vector-derived NT-3	18788
@NP	recombinant NT-3	18857
@NP	OEG	18902
@NP	3.2 In vivo analysis of transgene expression	18907
@NP	3.2 In vivo analysis	18907
@NP	3.2	18907
@NP	In vivo analysis	18911
@NP	transgene expression	18931
@NP	7 d	18955
@NP	implantation	18965
@NP	transgene expression in OEG implants	18979
@NP	transgene expression	18979
@NP	OEG implants	19003
@NP	RT-PCR	19032
@NP	The tissue from rats in pcDNA3 .1 -LRB- + -RRB- - NT3-tansfected OEG group	19040
@NP	The tissue	19040
@NP	rats in pcDNA3 .1 -LRB- + -RRB- - NT3-tansfected OEG group	19056
@NP	rats	19056
@NP	pcDNA3 .1 -LRB- + -RRB- - NT3-tansfected OEG group	19064
@NP	pcDNA3 .1	19064
@NP	+	19073
@NP	NT3-tansfected OEG group	19077
@NP	high levels of NT-3 mRNA -LRB- Fig. 2 -RRB-	19112
@NP	high levels	19112
@NP	NT-3 mRNA -LRB- Fig. 2 -RRB-	19127
@NP	NT-3 mRNA	19127
@NP	Fig. 2	19138
@NP	3.3 Axonal survival and regeneration	19147
@NP	3.3 Axonal survival	19147
@NP	regeneration	19171
@NP	axonal survival and regeneration	19196
@NP	NF immunoreactivity	19230
@NP	12 weeks	19266
@NP	The significantly more NF-positive axons	19288
@NP	the pcDNA3	19341
@NP	+	19354
@NP	NT3-tansfected OEG group	19357
@NP	pcDNA3 .1 -LRB- + -RRB- - transfected and untransfected	19390
@NP	pcDNA3 .1	19390
@NP	+	19399
@NP	OEG groups	19432
@NP	untreated group -LRB- Fig. 3 ; P < 0.05 -RRB-	19447
@NP	untreated group	19447
@NP	Fig. 3 ; P < 0.05	19464
@NP	Fig. 3	19464
@NP	P < 0.05	19472
@NP	P <	19472
@NP	P	19472
@NP	0.05	19476
@NP	The FG labeling	19483
@NP	retrograde transportation of regenerated fibers	19511
@NP	retrograde transportation	19511
@NP	regenerated fibers	19540
@NP	the glial scar	19568
@NP	the distal part of spinal cord	19599
@NP	the distal part	19599
@NP	spinal cord	19618
@NP	the lesion regions	19638
@NP	Some labeled neurons	19658
@NP	Some	19658
@NP	neurons	19671
@NP	the cervical spinal cord and some parts of the cerebrum	19696
@NP	the cervical spinal cord	19696
@NP	some parts of the cerebrum	19725
@NP	some parts	19725
@NP	the cerebrum	19739
@NP	cortex -LRB- Fig. 4 -RRB-	19763
@NP	cortex	19763
@NP	Fig. 4	19771
@NP	3.4 Functional recovery	19780
@NP	some of the rats	19819
@NP	some	19819
@NP	the rats	19827
@NP	cystitis or other infections	19846
@NP	the numbers of rats	19879
@NP	the numbers	19879
@NP	rats	19894
@NP	the 12th week after SCI were 10 in the pcDNA3	19914
@NP	the 12th week	19914
@NP	SCI	19934
@NP	10 in the pcDNA3	19943
@NP	10	19943
@NP	the pcDNA3	19949
@NP	+	19963
@NP	NT3-transfected OEG group , 9 in the untransfected OEG group	19966
@NP	NT3-transfected OEG group	19966
@NP	9 in the untransfected OEG group	19993
@NP	9	19993
@NP	the untransfected OEG group	19998
@NP	9 in the pcDNA3 .1 -LRB- + -RRB-	20027
@NP	9	20027
@NP	the pcDNA3 .1 -LRB- + -RRB-	20032
@NP	the pcDNA3 .1	20032
@NP	+	20045
@NP	transfected OEG group and 7	20048
@NP	transfected OEG group	20048
@NP	7	20074
@NP	untreated group	20079
@NP	Blind functional assessments and analyses	20096
@NP	Blind functional assessments	20096
@NP	analyses	20129
@NP	the BBB open field locomotion scale	20162
@NP	The rats	20199
@NP	either paralysis or durative uncoordinated hindlimb spasms	20228
@NP	paralysis	20235
@NP	durative uncoordinated hindlimb spasms	20248
@NP	Three weeks	20288
@NP	SCI	20306
@NP	initial paralysis	20311
@NP	the animals	20347
@NP	pcDNA3 .1 -LRB- + -RRB-	20374
@NP	pcDNA3 .1	20374
@NP	+	20383
@NP	NT3-transfected OEG -LRB- Fig. 5 -RRB-	20386
@NP	NT3-transfected OEG	20386
@NP	Fig. 5	20407
@NP	Six weeks	20416
@NP	SCI	20432
@NP	they	20437
@NP	extensive joint movement	20455
@NP	their hindlimbs	20483
@NP	their BBB score	20504
@NP	the other three groups -LRB- P < 0.05 -RRB-	20558
@NP	the other three groups	20558
@NP	P < 0.05	20582
@NP	P	20582
@NP	< 0.05	20584
@NP	<	20584
@NP	0.05	20586
@NP	The mean BBB scores at 12-week	20593
@NP	The mean BBB scores	20593
@NP	12-week	20616
@NP	12.50	20629
@NP	10.39	20636
@NP	10.22 and 3.78 , respectively	20643
@NP	10.22 and 3.78	20643
@NP	pcDNA3 .1 -LRB- + -RRB- - NT3 + OEG , OEG , pcDNA3 .1 -LRB- + -RRB- + OEG	20676
@NP	pcDNA3	20676
@NP	+	20685
@NP	- NT3 + OEG , OEG , pcDNA3 .1 -LRB- + -RRB- + OEG	20687
@NP	- NT3 + OEG , OEG , pcDNA3 .1	20687
@NP	NT3 + OEG	20688
@NP	NT3	20688
@NP	OEG	20692
@NP	OEG , pcDNA3 .1	20696
@NP	OEG	20696
@NP	pcDNA3 .1	20701
@NP	+ OEG	20712
@NP	Rats	20740
@NP	the pcDNA3	20748
@NP	+	20761
@NP	- NT3-transfected OEG group had better performances compared with those in	20763
@NP	NT3-transfected OEG	20764
@NP	group had better performances compared	20784
@NP	group	20784
@NP	better performances	20794
@NP	those	20828
@NP	other groups	20837
@NP	P < 0.05	20851
@NP	P	20851
@NP	< 0.05	20853
@NP	<	20853
@NP	0.05	20855
@NP	The pcDNA3 .1 -LRB- + -RRB-	20862
@NP	The pcDNA3 .1	20862
@NP	+	20875
@NP	transfected OEG group and the untransfected OEG group	20878
@NP	transfected OEG group	20878
@NP	the untransfected OEG group	20904
@NP	no significantly difference	20936
@NP	Discussion	20969
@NP	OEG implantation	20993
@NP	ex vivo plasmid vector-mediated NT-3 gene transfer	21015
@NP	ex vivo plasmid	21015
@NP	vector-mediated NT-3 gene transfer	21031
@NP	we	21067
@NP	the following results	21083
@NP	this study	21108
@NP	OEG	21124
@NP	plasmid , a non-viral vector , mediated with cationic liposome	21164
@NP	plasmid	21164
@NP	a non-viral vector	21173
@NP	cationic liposome	21207
@NP	OEG	21239
@NP	both ex vivo	21255
@NP	the recombinant NT-3 protein	21292
@NP	biological activity	21326
@NP	The NT3-transfected OEG implants	21351
@NP	recovery of hindlimb function	21393
@NP	recovery	21393
@NP	hindlimb function	21405
@NP	behavioral testing	21440
@NP	Quantitative histological	21464
@NP	the NT3-transfected OEG implants	21502
@NP	the axonal regeneration	21547
@NP	injured spinal cord	21581
@NP	genetic modified OEG	21613
@NP	the injured spinal cord	21645
@NP	simple OEG	21681
@NP	many problems	21702
@NP	we	21733
@NP	that OEG combined with gene therapy	21745
@NP	that OEG	21745
@NP	gene therapy	21768
@NP	a promising strategy	21784
@NP	Gene therapy	21806
@NP	delivery of nucleic acids	21839
@NP	delivery	21839
@NP	nucleic acids	21851
@NP	patients via a vector for therapeutic purposes	21868
@NP	patients	21868
@NP	a vector for therapeutic purposes	21881
@NP	a vector	21881
@NP	therapeutic purposes	21894
@NP	This	21916
@NP	a promising therapeutic method	21924
@NP	currently enormous failure of clinical trials	21962
@NP	currently enormous failure	21962
@NP	clinical trials	21992
@NP	The primary reason for current failure and frustration	22009
@NP	The primary reason	22009
@NP	current failure and frustration	22032
@NP	no adequate vectors	22072
@NP	therapeutic nucleic acids	22117
@NP	their desired site of action in the chosen cells	22146
@NP	their desired site	22146
@NP	action in the chosen cells	22168
@NP	action	22168
@NP	the chosen cells	22178
@NP	There	22196
@NP	two kinds	22206
@NP	vectors , viral and non-viral vector system	22219
@NP	vectors	22219
@NP	viral	22228
@NP	non-viral vector system	22238
@NP	gene delivery	22272
@NP	Synthetic non-viral vector systems	22287
@NP	many advantages compared with viral systems	22327
@NP	many advantages	22327
@NP	viral systems	22357
@NP	significantly lower toxicity/immunogenicity and potential for oncogenicity	22382
@NP	significantly lower toxicity/immunogenicity	22382
@NP	potential for oncogenicity	22430
@NP	potential	22430
@NP	oncogenicity	22444
@NP	size independent delivery	22458
@NP	nucleic acids -LRB- from oligonucleotides to artificial chromosomes -RRB-	22487
@NP	nucleic acids	22487
@NP	oligonucleotides to artificial chromosomes	22507
@NP	oligonucleotides	22507
@NP	artificial chromosomes	22527
@NP	simpler quality control	22552
@NP	substantially easier pharmaceutical	22581
@NP	regulatory requirements -LSB- 19 -RSB-	22621
@NP	regulatory requirements	22621
@NP	19 -RSB-	22645
@NP	public alarm	22661
@NP	the toxic side effects of virus	22692
@NP	the toxic side effects	22692
@NP	virus	22718
@NP	these significant advantages	22746
@NP	Basic clinical confidence in non-viral vectors	22776
@NP	Basic clinical confidence	22776
@NP	non-viral vectors	22805
@NP	the various advantages	22838
@NP	inherent in synthetic non-viral vector systems	22874
@NP	synthetic non-viral vector	22886
@NP	substantial clinical uptake	22935
@NP	the science and technology of these vector systems	22968
@NP	the science and technology	22968
@NP	these vector systems	22998
@NP	routine clinical use	23052
@NP	our original proof of present study	23077
@NP	our original proof	23077
@NP	present study	23099
@NP	we	23114
@NP	cationic liposome	23128
@NP	delivery of recombinant NT-3 cDNA	23160
@NP	delivery	23160
@NP	recombinant NT-3 cDNA	23172
@NP	OEG	23197
@NP	production	23223
@NP	therapeutic levels of functional NT-3 protein in injured spinal cord	23237
@NP	therapeutic levels	23237
@NP	functional NT-3 protein in injured spinal cord	23259
@NP	functional NT-3 protein	23259
@NP	injured spinal cord	23286
@NP	Neurotrophins	23307
@NP	biological effects	23327
@NP	their specific combination with the receptor	23359
@NP	their specific combination	23359
@NP	the receptor	23391
@NP	A kind of neurotrophin	23405
@NP	A kind	23405
@NP	neurotrophin	23415
@NP	some specific neurites	23444
@NP	SCI of mammalian	23474
@NP	SCI	23474
@NP	mammalian	23481
@NP	the recovery	23492
@NP	corticospinal tract -LRB- CST -RRB- and main sensory pathway	23508
@NP	corticospinal tract -LRB- CST -RRB-	23508
@NP	corticospinal tract	23508
@NP	CST	23529
@NP	main sensory pathway	23538
@NP	NT-3 receptors	23566
@NP	NT-3	23621
@NP	the appropriate candidate -LSB- 20 -RSB-	23629
@NP	the appropriate candidate	23629
@NP	20 -RSB-	23655
@NP	Many researches	23660
@NP	Many	23660
@NP	NT-3	23692
@NP	the survival of sensory , motor and sympathetic neurons	23710
@NP	the survival	23710
@NP	sensory , motor and sympathetic neurons	23726
@NP	neuronal apoptosis	23774
@NP	SCI	23799
@NP	the axonal regeneration	23814
@NP	the ability of promoting axonal regeneration	23842
@NP	the ability	23842
@NP	axonal regeneration	23867
@NP	NT-3	23888
@NP	nerve growth factor	23900
@NP	NGF	23921
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB- -LSB- 21 -RSB-	23929
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	23929
@NP	brain-derived neurotrophic factor	23929
@NP	BDNF	23964
@NP	21 -RSB-	23970
@NP	date	23978
@NP	a number of axon populations	23984
@NP	a number	23984
@NP	axon populations	23996
@NP	OEG implants in different injury models	24049
@NP	OEG implants	24049
@NP	different injury models	24065
@NP	sensory axons	24100
@NP	the dorsal root axons -LSB- 21,22	24117
@NP	the dorsal root axons	24117
@NP	21,22	24139
@NP	serotonergic axons -LSB- 8,9,24,25	24157
@NP	serotonergic axons	24157
@NP	8,9,24,25	24176
@NP	CST axons -LSB- 7,8 -RSB-	24191
@NP	CST axons	24191
@NP	7,8 -RSB-	24201
@NP	Some controversy	24207
@NP	the regenerative response of the CST	24238
@NP	the regenerative response	24238
@NP	the CST	24267
@NP	others	24283
@NP	OEG	24301
@NP	the proximal injury site -LSB- 26 -RSB-	24338
@NP	the proximal injury site	24338
@NP	26 -RSB-	24363
@NP	the present study	24371
@NP	a significant axonal regeneration and better recovery of locomotion function	24390
@NP	a significant axonal regeneration	24390
@NP	better recovery of locomotion function	24428
@NP	better recovery	24428
@NP	locomotion function	24447
@NP	implantation of OEG transfected with NT-3	24483
@NP	implantation	24483
@NP	OEG transfected with NT-3	24499
@NP	OEG	24499
@NP	NT-3	24520
@NP	plasmid	24535
@NP	no fully recovery of locomotion	24548
@NP	no fully recovery	24548
@NP	locomotion	24569
@NP	it	24600
@NP	no sufficient NT-3 was produced by the OEG transfected with non-viral vector	24613
@NP	no sufficient NT-3	24613
@NP	the OEG transfected with non-viral vector	24648
@NP	the OEG	24648
@NP	non-viral vector	24673
@NP	we	24695
@NP	no fully recovery of locomotion	24722
@NP	no fully recovery	24722
@NP	locomotion	24743
@NP	previous study using viral vector -LSB- 16,27 -RSB-	24777
@NP	previous study	24777
@NP	viral vector -LSB- 16,27 -RSB-	24798
@NP	viral vector	24798
@NP	16,27 -RSB-	24811
@NP	we	24822
@NP	the repair of injured spinal cord	24831
@NP	the repair	24831
@NP	injured spinal cord	24845
@NP	the balance between promoter and inhibitor	24876
@NP	the balance	24876
@NP	promoter and inhibitor	24896
@NP	the single use	24923
@NP	promoter such as OEG or neurotrophin without dealing with inhibitor such as Nogo	24941
@NP	promoter	24941
@NP	OEG or neurotrophin without dealing with inhibitor such as Nogo	24958
@NP	OEG or neurotrophin	24958
@NP	inhibitor such as Nogo	24999
@NP	inhibitor	24999
@NP	Nogo	25017
@NP	nerve regeneration	25071
@NP	It	25091
@NP	more insight	25127
@NP	overall requirements of injured spinal cord	25143
@NP	overall requirements	25143
@NP	injured spinal cord	25167
@NP	Extended knowledge	25188
@NP	both promotion factors and inhibition ones	25210
@NP	promotion factors	25215
@NP	inhibition ones	25237
@NP	regeneration of nerve tracts	25265
@NP	regeneration	25265
@NP	nerve tracts	25281
@NP	the development of more optimal microenvironment	25305
@NP	the development	25305
@NP	more optimal microenvironment	25324
@NP	The combination of neural transplantation and neurotrophin delivery	25355
@NP	The combination	25355
@NP	neural transplantation and neurotrophin delivery	25374
@NP	a promising strategy	25438
@NP	regeneration and functional recovery	25470
@NP	spinal cord injury -LSB- 28,29 -RSB-	25513
@NP	spinal cord injury	25513
@NP	28,29 -RSB-	25532
@NP	We	25540
@NP	ex vivo transfection of OEG with NT-3-encoding plasmid vectors	25560
@NP	ex vivo transfection	25560
@NP	OEG with NT-3-encoding plasmid vectors	25584
@NP	OEG	25584
@NP	NT-3-encoding plasmid vectors	25593
@NP	axonal regeneration	25654
@NP	2	25676
@NP	the growth-promoting properties of these cells	25687
@NP	the growth-promoting properties	25687
@NP	these cells	25722
@NP	-LRB- 3 -RRB- improve functional recovery after implantation	25739
@NP	improve functional recovery	25743
@NP	implantation	25777
@NP	A limitation of only neurotrophintransfected OEG implants	25791
@NP	A limitation	25791
@NP	only neurotrophintransfected OEG implants	25807
@NP	they	25857
@NP	inhibitors	25881
@NP	another important factor affecting repair of injured spinal cord	25911
@NP	another important factor	25911
@NP	repair of injured spinal cord	25946
@NP	repair	25946
@NP	injured spinal cord	25956
@NP	Combination of promoter and inhibitor antagonist	25977
@NP	Combination	25977
@NP	promoter and inhibitor antagonist	25992
@NP	the results	26054
@NP	hope	26083
@NP	the use of these modified cells in both acute and chronic SCI models	26092
@NP	the use	26092
@NP	these modified cells in both acute and chronic SCI models	26103
@NP	these modified cells	26103
@NP	both acute and chronic SCI models	26127
@VP	to enhance regeneration after thoracic spinal cord injury -LRB- SCI -RRB-	415
@VP	enhance regeneration after thoracic spinal cord injury -LRB- SCI -RRB-	418
@VP	transfected with cationic liposome-mediated recombinant plasmid pcDNA3 .1	505
@VP	subsequently implanted into adult Wistar rats	589
@VP	transfected with pcDNA3 .1	780
@VP	was implanted	952
@VP	implanted	956
@VP	was seen	991
@VP	seen	995
@VP	increased both ex vivo and in vivo in pcDNA3 .1 -LRB- + -RRB-	1000
@VP	transfected OEGs	1054
@VP	revealed that the hindlimb function of SCI rats was improved	1150
@VP	was improved	1198
@VP	improved	1202
@VP	were filled with regenerated neurofilament-positive axons	1229
@VP	filled with regenerated neurofilament-positive axons	1234
@VP	regenerated neurofilament-positive axons	1246
@VP	tracing	1299
@VP	revealed enhanced regenerative axonal sprouting	1307
@VP	enhanced regenerative axonal sprouting	1316
@VP	sprouting	1345
@VP	producing NT - 3	1451
@VP	promoting axonal outgrowth followed by enhancing SCI recovery in rats	1471
@VP	enhancing SCI recovery in rats	1510
@VP	attributed to disruption of descending motor pathways and ascending sensory ones	1643
@VP	descending motor pathways and ascending sensory ones	1671
@VP	descending motor pathways	1671
@VP	ascending sensory ones	1701
@VP	leading to permanent loss of function and paralysis	1830
@VP	is no available therapy for restoration of function at present	1889
@VP	have researched strategies for the restoration of function resulting from SCI	1972
@VP	researched strategies for the restoration of function resulting from SCI	1977
@VP	resulting from SCI	2031
@VP	has emerged as a promising strategy -LSB- 1-3 -RSB-	2080
@VP	emerged as a promising strategy -LSB- 1-3 -RSB-	2084
@VP	grow into adult CNS , find their appropriate targets ,	2208
@VP	find their appropriate targets	2229
@VP	form synaptic contacts with them -LSB- 4 -RSB-	2265
@VP	to regenerate and form specific connections	2355
@VP	regenerate and form specific connections	2358
@VP	-LSB- 5 -RSB-	2568
@VP	seem to have great potential to repair damaged spinal cord -LSB- 2,5-9 -RSB-	2576
@VP	to have great potential to repair damaged spinal cord -LSB- 2,5-9 -RSB-	2581
@VP	have great potential to repair damaged spinal cord -LSB- 2,5-9 -RSB-	2584
@VP	to repair damaged spinal cord -LSB- 2,5-9 -RSB-	2605
@VP	repair damaged spinal cord -LSB- 2,5-9 -RSB-	2608
@VP	grow into OEG implants -LSB- 10 -RSB-	2679
@VP	expressed by OEG	2852
@VP	is low -LSB- 11,12 -RSB-	2869
@VP	known for their beneficial effects on neurite outgrowth and neuroprotection	2907
@VP	is one of important factors in regenerative milieu	3006
@VP	are focused on the usage of NT-3 stimulating nerve regeneration	3149
@VP	focused on the usage of NT-3 stimulating nerve regeneration	3153
@VP	provides a new strategy for application of NT-3	3398
@VP	allows	3450
@VP	would then produce NT-3 continuously and exert the physiological action	3496
@VP	produce NT-3 continuously and exert the physiological action	3507
@VP	produce NT-3 continuously	3507
@VP	exert the physiological action	3537
@VP	attempting to create more conducive conditions for axonal regeneration	3688
@VP	to create more conducive conditions for axonal regeneration	3699
@VP	create more conducive conditions for axonal regeneration	3702
@VP	were used to assess regeneration in animals over a 12-week observation period	3939
@VP	used to assess regeneration in animals over a 12-week observation period	3944
@VP	to assess regeneration in animals over a 12-week observation period	3949
@VP	assess regeneration in animals over a 12-week observation period	3952
@VP	amplified by PCR from gene got from rat liver cells	4122
@VP	got from rat liver cells	4149
@VP	cloned into pcDNA3 .1 -LRB- + -RRB-	4178
@VP	restricting enzyme digestion and DNA sequencing	4244
@VP	to demonstrate the sequence of plasmid as described previously -LSB- 14 -RSB-	4309
@VP	demonstrate the sequence of plasmid as described previously -LSB- 14 -RSB-	4312
@VP	described previously -LSB- 14 -RSB-	4351
@VP	has been described previously -LSB- 15 -RSB-	4455
@VP	been described previously -LSB- 15 -RSB-	4459
@VP	described previously -LSB- 15 -RSB-	4464
@VP	killed by intraperitoneal injection of a lethal dose of pentobarbital	4525
@VP	decapitated	4599
@VP	was quickly performed under sterile conditions to expose the olfactory bulb	4625
@VP	quickly performed under sterile conditions to expose the olfactory bulb	4629
@VP	to expose the olfactory bulb	4672
@VP	expose the olfactory bulb	4675
@VP	was dissected	4721
@VP	dissected	4725
@VP	rinsed twice with ice cold HBSS and then minced with a sterile scalpel blade	4839
@VP	rinsed twice with ice cold HBSS	4839
@VP	then minced with a sterile scalpel blade	4875
@VP	suspended in 5 mL of HBSS with 1 mg/mL trypsin	4949
@VP	incubated at 37 °C for 15 min	5000
@VP	supplemented with 10 % fetal bovine serum -LRB- DF-10S ; Invitrogen -RRB-	5115
@VP	was added to stop the trypsinization	5177
@VP	added to stop the trypsinization	5181
@VP	to stop the trypsinization	5187
@VP	stop the trypsinization	5190
@VP	was centrifuged briefly	5231
@VP	centrifuged briefly	5235
@VP	was aspirated	5272
@VP	aspirated	5276
@VP	were multiply rinsed with DF-10S	5300
@VP	multiply rinsed with DF-10S	5305
@VP	rinsed with DF-10S	5314
@VP	supplemented with L-glutamine -LRB- 20 mmol/L -RRB-	5356
@VP	was added	5442
@VP	added	5446
@VP	passed through a 70-μm mesh filter	5466
@VP	was checked for viability with 0.1 % trypan blue	5522
@VP	checked for viability with 0.1 % trypan blue	5526
@VP	were counted with a hemocytometer	5581
@VP	counted with a hemocytometer	5586
@VP	diluted to 1 × 106 cells/mL	5640
@VP	plated onto 25 cm2 flask pretreated with poly-D-lysin -LRB- 0.2 mg/mL -RRB-	5670
@VP	pretreated with poly-D-lysin -LRB- 0.2 mg/mL -RRB-	5695
@VP	incubated for 7 d at 37 oC with 5 % CO2 , with culture medium changed every 2 d.	5748
@VP	changed every 2 d.	5808
@VP	using the serum-free medium -LRB- SFM -RRB- instead of DF-10S	5905
@VP	to transfer the plasmids into OEG	6333
@VP	transfer the plasmids into OEG	6336
@VP	was performed according to the instructions of manufacturer	6391
@VP	performed according to the instructions of manufacturer	6395
@VP	would be 90 % -95 % confluent at the time of transfection	6579
@VP	be 90 % -95 % confluent at the time of transfection	6585
@VP	Dilute plasmid in 50 μL of Opti-MEM	6635
@VP	Reduced Serum Medium without serum and mix gently	6673
@VP	dilute the appropriate amount in 50 μL of Opti-MEM I Medium	6770
@VP	incubate for 5 min at room temperature	6846
@VP	combine the diluted DNA with the diluted Lipofectamine2000	6914
@VP	to allow the formation of plasmid - Lipofectamine2000 complexes	7029
@VP	allow the formation of plasmid - Lipofectamine2000 complexes	7032
@VP	Add the complexes to each well	7093
@VP	rocking the plate back and forth	7139
@VP	were ready to assay for transgene expression	7243
@VP	were determined by ELISA , as described by Woodhall et al. -LSB- 12 -RSB-	7418
@VP	determined by ELISA , as described by Woodhall et al. -LSB- 12 -RSB-	7423
@VP	described by Woodhall et al. -LSB- 12 -RSB-	7447
@VP	was refreshed 3 d post-transfection	7492
@VP	refreshed 3 d post-transfection	7496
@VP	were left for 24 h for determination of the production per day	7545
@VP	left for 24 h for determination of the production per day	7550
@VP	was used to assess the NT-3 levels in OEG conditioned medium	7647
@VP	used to assess the NT-3 levels in OEG conditioned medium	7651
@VP	to assess the NT-3 levels in OEG conditioned medium	7656
@VP	assess the NT-3 levels in OEG conditioned medium	7659
@VP	secreted from 1 × 105 transfected cells per day	7728
@VP	transfected cells per day	7748
@VP	was recorded	7774
@VP	recorded	7778
@VP	To determine whether recombinant NT-3 protein was biologically active	7843
@VP	determine whether recombinant NT-3 protein was biologically active	7846
@VP	was biologically active	7889
@VP	studied their effects on the neurite outgrowth in human neuroblastoma cells	7917
@VP	were collected and cultured routinely	8028
@VP	collected and cultured routinely	8033
@VP	were trypsinized by 0.05 % trypsin -LRB- Invitrogen -RRB- for 10 min	8086
@VP	trypsinized by 0.05 % trypsin -LRB- Invitrogen -RRB- for 10 min	8091
@VP	supplemented with 10 % fetal bovine serum -LRB- DF-10S ; Invitrogen -RRB-	8230
@VP	washed twice in serum-free medium	8312
@VP	seeded onto 4 plates at a density of 1 ×	8350
@VP	, or OEGs without plasmid transfection , was added to 3 different	8486
@VP	, or OEGs without plasmid transfection , was added to	8486
@VP	was added with serum-free medium	8574
@VP	added with serum-free medium	8578
@VP	was photographed	8644
@VP	photographed	8648
@VP	were prepared as Ruitenberg et al. described -LSB- 16 -RSB-	8725
@VP	prepared as Ruitenberg et al. described -LSB- 16 -RSB-	8730
@VP	described -LSB- 16 -RSB-	8760
@VP	Purified OEGs	8775
@VP	were seeded onto poly-L-lysine-coated dishes at a density of 1 ×	8789
@VP	seeded onto poly-L-lysine-coated dishes at a density of 1 ×	8794
@VP	containing pcDNA3 .1 -LRB- + -RRB- - NT3 or pcDNA3 .1 -LRB- + -RRB- , and cells	8929
@VP	.1 -LRB- + -RRB- - NT3 or pcDNA3 .1 -LRB- + -RRB- , and cells	8946
@VP	+	8968
@VP	were left for 72 h.	8982
@VP	left for 72 h.	8987
@VP	washed with L-15 medium	9036
@VP	detached by trypsinization	9061
@VP	washed twice in serum-free DMEM/F -12 medium	9092
@VP	pelleted by low-speed centrifugation	9154
@VP	carefully resuspended	9192
@VP	to obtain the OEG suspension at 50 000 / μL	9262
@VP	obtain the OEG suspension at 50 000 / μL	9265
@VP	was assessed by counting the percentage of dead cells using Trypan blue staining	9346
@VP	assessed by counting the percentage of dead cells using Trypan blue staining	9350
@VP	counting the percentage of dead cells using Trypan blue staining	9362
@VP	using Trypan blue staining	9400
@VP	was > 95 %	9428
@VP	raised under standard conditions with a 12/12 h light/dark cycle	9491
@VP	accessed to water and food ad libitum	9561
@VP	subjected to the thoracic spinal cord contusion	9789
@VP	then divided into four groups	9841
@VP	was untreated	9888
@VP	was evaluated weekly for 12 weeks	10180
@VP	evaluated weekly for 12 weeks	10184
@VP	were taken for evaluation of transgene expression	10269
@VP	taken for evaluation of transgene expression	10274
@VP	being killed	10341
@VP	killed	10347
@VP	were retrogradely labeled with fluorochrome -LRB- FG ; Vector Laboratories -RRB-	10388
@VP	labeled with fluorochrome -LRB- FG ; Vector Laboratories -RRB-	10406
@VP	was described previously in detail -LSB- 16 -RSB-	10551
@VP	described previously in detail -LSB- 16 -RSB-	10555
@VP	were anesthetized and underwent laminectomy at T9-T10	10609
@VP	were anesthetized	10609
@VP	underwent laminectomy at T9-T10	10631
@VP	using the New York University impactor -LSB- 17 -RSB-	10726
@VP	was confirmed	10805
@VP	confirmed	10809
@VP	were 1.75 mm , 1.25 mm , 1 mm , and 0.5 mm , respectively	11200
@VP	received 1 L of a suspension containing 5 × 104 cells	11265
@VP	containing 5 × 104 cells	11296
@VP	injected total 2 × 105 cells into each cord stump	11332
@VP	using a sterile glass micropipette , Hamilton syringe , and a micromanipulator	11407
@VP	to compensate for blood loss	11581
@VP	compensate for blood loss	11584
@VP	were expressed twice daily until reflexes returned	11630
@VP	expressed twice daily until reflexes returned	11635
@VP	returned	11672
@VP	were maintained in pairs in separate cages	11691
@VP	maintained in pairs in separate cages	11696
@VP	used for implantation	11803
@VP	still ranged between 90 % and 95 % as determined by Trypan blue staining	11825
@VP	was performed 7 d after implantation to evaluate transgene expression	11937
@VP	performed 7 d after implantation to evaluate transgene expression	11941
@VP	to evaluate transgene expression	11974
@VP	evaluate transgene expression	11977
@VP	using Test Kit following the manufacturer 's instructions	12074
@VP	was amplified by PCR	12151
@VP	amplified by PCR	12155
@VP	containing	12216
@VP	reverse	12291
@VP	followed by a final extension at 72 °C for 10 min	12470
@VP	were reviewed by a blinded scorer	12671
@VP	reviewed by a blinded scorer	12676
@VP	were assigned for each animal at each testing session	12755
@VP	assigned for each animal at each testing session	12760
@VP	were averaged	12846
@VP	averaged	12851
@VP	was submitted for each animal at each testing session	12879
@VP	submitted for each animal at each testing session	12883
@VP	tracing The regenerated axons	12955
@VP	was retrogradely traced with FG , as a neuronal label , 14 d before perfusion	12985
@VP	traced with FG , as a neuronal label , 14 d before perfusion	13002
@VP	was subsequently delivered to the spinal cord caudad to the lesion region	13202
@VP	delivered to the spinal cord caudad to the lesion region	13219
@VP	followed by careful withdrawal of the glass capillary and suturing of the skin	13319
@VP	were sacrificed 12 weeks post-operation	13431
@VP	sacrificed 12 weeks post-operation	13436
@VP	were harvested for immunohistochemical staining of neurofilament -LRB- NF -RRB-	13493
@VP	harvested for immunohistochemical staining of neurofilament -LRB- NF -RRB-	13498
@VP	containing heparin	13644
@VP	buffered paraformaldehyde	13679
@VP	cut and fixed in a 10 % formalin solution for 2 h	13745
@VP	embedded in paraffin	13795
@VP	cut in 4 μm sections	13822
@VP	were treated with 0.3 % H2O2 in methanol to inactivate the endogenous peroxidase	13857
@VP	treated with 0.3 % H2O2 in methanol to inactivate the endogenous peroxidase	13862
@VP	to inactivate the endogenous peroxidase	13897
@VP	inactivate the endogenous peroxidase	13900
@VP	was blocked with 3 % normal serum	13963
@VP	blocked with 3 % normal serum	13967
@VP	raised against NF	14016
@VP	was diluted in 1 % normal serum	14126
@VP	diluted in 1 % normal serum	14130
@VP	applied to the tissue	14158
@VP	followed by ABC complex for 45 min at room temperature	14360
@VP	was used as the chromatogen	14491
@VP	used as the chromatogen	14495
@VP	counterstained with hematoxylin , dehydrated in graded alcohols , and mounted	14538
@VP	counterstained with hematoxylin	14538
@VP	dehydrated in graded alcohols	14571
@VP	graded alcohols	14585
@VP	mounted	14606
@VP	stained with normal serum	14628
@VP	were used for control	14654
@VP	used for control	14659
@VP	resulted in only weak , nonspecific labeling of the blood vessels	14708
@VP	using a computer-assisted digital image analysis system -LRB- MPIAS-500 -RRB-	14866
@VP	to identify positive stained properties within a defined target area	14998
@VP	identify positive stained properties within a defined target area	15001
@VP	stained properties within a defined target area	15019
@VP	visualized as mentioned above and then observed under fluorescent microscope	15092
@VP	mentioned above	15106
@VP	observed under fluorescent microscope	15131
@VP	obtained from histological analysis and the BBB scores	15201
@VP	was considered statistically significant	15381
@VP	considered statistically significant	15385
@VP	incorporated in the analysis	15432
@VP	were obtained from the animals survived the entire study	15461
@VP	obtained from the animals survived the entire study	15466
@VP	survived the entire study	15492
@VP	cultured with medium from olfactory ensheathing glia -LRB- OEG -RRB- cultures	15563
@VP	were found when medium from the OEG transfected with NT-3	15890
@VP	found when medium from the OEG transfected with NT-3	15895
@VP	transfected with NT-3	15926
@VP	encoding plasmid vector	15949
@VP	was added	15973
@VP	added	15977
@VP	.1 -LRB- + -RRB- + OEG group ; Lane D : pcDNA3	16097
@VP	.1 -LRB- + -RRB- - NT3-tansfected OEG group expressed high level of NT-3 mRNA	16160
@VP	received pcDNA3 .1 -LRB- + -RRB- - NT3 transfected OEG revealed active	16353
@VP	revealed	16394
@VP	coordinated hindlimb movement six weeks later after injury	16410
@VP	were determined by post hoc means-corrected t-test -LRB- P < 0.05 -RRB-	16636
@VP	determined by post hoc means-corrected t-test -LRB- P < 0.05 -RRB-	16641
@VP	not shown	16972
@VP	came up to 30 % as determined by fluorescence assay	17008
@VP	determined by fluorescence assay	17026
@VP	served as control cultures or after hybridization with sense probe	17243
@VP	using an ELISA assay 4 d later after transfection	17397
@VP	taken from control or pcDNA3 .1 -LRB- + -RRB- - transfected OEG cultures	17502
@VP	taken from control or pcDNA3 .1 -LRB- + -RRB-	17502
@VP	transfected	17536
@VP	was secreted from 1	17693
@VP	secreted from 1	17697
@VP	were released from NT-3-transfected OEG as compared with controls	17837
@VP	released from NT-3-transfected OEG as compared with controls	17842
@VP	was demonstrated in a coculture experiment	17948
@VP	demonstrated in a coculture experiment	17952
@VP	to determine the effect of transgenic neurotrophic factor production	18081
@VP	determine the effect of transgenic neurotrophic factor production	18084
@VP	analyzed for neurite outgrowth at 3 d after the initial plating	18172
@VP	did not interfere with the growth supporting properties of OEG	18537
@VP	interfere with the growth supporting properties of OEG	18545
@VP	supporting properties of OEG	18571
@VP	transfected with a plasmid vector-encoding NT-3	18688
@VP	was added -LRB- Fig. 1C -RRB-	18736
@VP	added -LRB- Fig. 1C -RRB-	18740
@VP	was biologically active	18816
@VP	confirm that recombinant NT-3 was secreted by transfected OEG	18844
@VP	was secreted by transfected OEG	18874
@VP	secreted by transfected OEG	18878
@VP	transfected OEG	18890
@VP	was examined by RT-PCR	19016
@VP	examined by RT-PCR	19020
@VP	expressed high levels of NT-3 mRNA -LRB- Fig. 2 -RRB-	19102
@VP	To evaluate axonal survival and regeneration	19184
@VP	evaluate axonal survival and regeneration	19187
@VP	was assessed at 12 weeks post-injury	19250
@VP	assessed at 12 weeks post-injury	19254
@VP	overcame the glial scar	19559
@VP	regrew into the distal part of spinal cord through the lesion regions	19587
@VP	labeled neurons	19663
@VP	died from cystitis or other infections	19836
@VP	were 10 in the pcDNA3	19938
@VP	were performed by using the BBB open field locomotion scale	20138
@VP	performed by using the BBB open field locomotion scale	20143
@VP	using the BBB open field locomotion scale	20156
@VP	exhibited either paralysis or durative uncoordinated hindlimb spasms	20218
@VP	implanted with pcDNA3 .1 -LRB- + -RRB- - NT3-transfected OEG -LRB- Fig. 5 -RRB-	20359
@VP	demonstrated extensive joint movement in their hindlimbs	20442
@VP	.1 -LRB- + -RRB- - NT3 + OEG , OEG , pcDNA3 .1 -LRB- + -RRB- + OEG	20682
@VP	+	20710
@VP	had better performances compared	20790
@VP	compared	20814
@VP	had no significantly difference	20932
@VP	demonstrated the following results in this study	21070
@VP	mediated with cationic liposome	21193
@VP	can survive both ex vivo and in vivo	21243
@VP	survive both ex vivo and in vivo	21247
@VP	expressing the recombinant NT-3 protein with biological activity	21281
@VP	improved recovery of hindlimb function as determined by behavioral testing	21384
@VP	determined by behavioral testing	21426
@VP	to repair injured spinal cord	21571
@VP	repair injured spinal cord	21574
@VP	indicating genetic modified OEG	21602
@VP	can repair the injured spinal cord better than simple OEG	21634
@VP	repair the injured spinal cord better than simple OEG	21638
@VP	remain unsolved	21716
@VP	consider that OEG combined with gene therapy is a promising strategy	21736
@VP	is a promising strategy	21781
@VP	used for gene delivery	22263
@VP	Increasing public alarm particularly with the toxic side effects of virus	22650
@VP	is also strengthening these significant advantages	22724
@VP	strengthening these significant advantages	22732
@VP	is growing	22823
@VP	listed above inherent in synthetic non-viral vector systems	22861
@VP	can be appropriately matured for routine clinical use	23019
@VP	be appropriately matured for routine clinical use	23023
@VP	appropriately matured for routine clinical use	23026
@VP	can only affect some specific neurites	23428
@VP	affect some specific neurites	23437
@VP	exist widely	23581
@VP	will be significative	23595
@VP	be significative	23600
@VP	is the appropriate candidate -LSB- 20 -RSB-	23626
@VP	researches	23665
@VP	maintain the survival of sensory , motor and sympathetic neurons	23701
@VP	prevent neuronal apoptosis after SCI	23766
@VP	induce the axonal regeneration	23807
@VP	promoting axonal regeneration	23857
@VP	to regenerate through OEG implants in different injury models	24027
@VP	regenerate through OEG implants in different injury models	24030
@VP	induced sprouting was limited to the proximal injury site -LSB- 26 -RSB-	24305
@VP	sprouting	24313
@VP	was limited to the proximal injury site -LSB- 26 -RSB-	24323
@VP	limited to the proximal injury site -LSB- 26 -RSB-	24327
@VP	was found after implantation of OEG transfected with NT-3 - encoding plasmid	24467
@VP	found after implantation of OEG transfected with NT-3 - encoding plasmid	24471
@VP	transfected with NT-3	24503
@VP	encoding plasmid	24526
@VP	was observed	24580
@VP	observed	24584
@VP	was produced by the OEG transfected with non-viral vector	24632
@VP	produced by the OEG transfected with non-viral vector	24636
@VP	transfected with non-viral vector	24656
@VP	was observed either in previous study using viral vector -LSB- 16,27 -RSB-	24754
@VP	observed either in previous study using viral vector -LSB- 16,27 -RSB-	24758
@VP	using viral vector -LSB- 16,27 -RSB-	24792
@VP	know	24825
@VP	depends on the balance between promoter and inhibitor	24865
@VP	dealing with inhibitor such as Nogo	24986
@VP	would lead to unbalance which is not optimum for nerve regeneration	25022
@VP	lead to unbalance which is not optimum for nerve regeneration	25028
@VP	to unbalance which is not optimum for nerve regeneration	25033
@VP	unbalance which is not optimum for nerve regeneration	25036
@VP	is not optimum for nerve regeneration	25052
@VP	to obtain more insight in overall requirements of injured spinal cord	25117
@VP	obtain more insight in overall requirements of injured spinal cord	25120
@VP	involved in regeneration of nerve tracts	25253
@VP	will allow the development of more optimal microenvironment	25294
@VP	allow the development of more optimal microenvironment	25299
@VP	did	25623
@VP	promote axonal regeneration	25646
@VP	is another important factor affecting repair of injured spinal cord	25908
@VP	affecting repair of injured spinal cord	25936
